The predictive effect of direct-indirect bilirubin ratio on clinical events in acute coronary syndrome: results from an observational cohort study in north China

Jiayu Li†, Yanguo Xin†, Jingye Li†, Meng Meng†, Li Zhou†, Hui Qiu†, Hui Chen† and Hongwei Li1,2,3*

Abstract

Background: Patients with extremely high-risk ASCVD usually suffered poor prognosis, bilirubin is considered closely related to cardiovascular outcomes. However, there is controversy over the relationship between bilirubin and coronary artery disease. This study aimed to evaluate the predictive value of the DIBIL ratio in patients with extremely high-risk ASCVD.

Methods: 10,260 consecutive patients with extremely high-risk ASCVD were enrolled in this study. All patients were divided into three groups according to their DIBIL ratio. The incidence of MACCEs was recorded, and in a competing risk regression, the incidence of MACCEs and their subgroups were recorded. The direct-indirect bilirubin ratio (DIBIL ratio) was calculated by the direct bilirubin (umol/L)/indirect bilirubin (umol/L) ratio, all laboratory values were obtained from the first fasting blood samples during hospitalization.

Results: The area under the ROC curve of the DIBIL ratio to predict the occurrence of all-cause death was 0.668, the cut-off value of which is 0.275. Competing risk regression indicated that DIBIL ratio was positively correlated with all-cause death [1.829 (1.405–2.381), p < 0.001], CV death [1.600 (1.103, 2.321), p = 0.013]. The addition of DIBIL ratio to a baseline risk model had an incremental effect on the predictive value for all-cause death [IDI 0.004(0, 0.010), p < 0.001; C-index 0.805(0.783–0.827), p < 0.001].

Conclusion: The DIBIL ratio was an excellent tool to predict poor prognosis, suggesting that this index may be developed as a biomarker for risk stratification and prognosis in extremely ASCVD patients.

Keywords: Bilirubin, Chinese, Extremely high-risk, ASCVD, DIBIL ratio

†Jiayu Li and Yanguo Xin contributed equally to this work.

*Correspondence:
Hongwei Li
lhw19656@sina.com
1Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong’an Road, Xicheng District, 100050 Beijing, China
2Department of Internal Medical, Medical Health Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
3Beijing Key Laboratory of Metabolic Disorder Related Cardiovascular Disease, Beijing, China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

CAD has been the first killer both in China and worldwide [1–3]. According to a report in 2013, the number of CAD deaths had reached 3.72 million in China [2]. For decades, various tools are developed to evaluate the risk of CAD risks, such as the SCORE model in Europe [4], and PCE for ASCVD [5]. According to China's cardiovascular prevention guideline in 2017, the risk evaluation of ASCVD is necessary to help physicians guide the best preventive approaches via a more accurate estimation of the risk of ASCVD. Patients diagnosed with extremely high-risk ASCVD are associated with a significantly elevated risk of recurrent MACCEs, indicating that early biomarkers or more details of this group of patients may contribute to a positive prognosis.

A large body of evidence reported that many clinical and laboratory factors were associated with the prognosis in ACS patients [6–8], bilirubin is the end-product of heme degradation, presenting in two forms: DB and IDB. IDB could be converted to DB in hepatocytes and excreted into bile acid [9]. Earlier studies reported that bilirubin is a waste product, however, recent evidence indicated that bilirubin possessed protective effects [10]. Animal models of atherosclerosis and myocardial infarction also showed that bilirubin could improve vascular dysfunction. The reported underlying mechanisms included anti-oxidative, anti-inflammatory, and anti-adipogenic effects of bilirubin. However, studies of the association between bilirubin levels and prognosis in CVD patients provided conflicting results, indicating an inverse relationship between bilirubin and mortality [11–14]. After analysis of the characteristics of patients enrolled in these studies, several factors such as the sample size, and the levels of bilirubin may contribute to different even opposite conclusions. In addition, there is still controversy over which parameters (direct bilirubin, indirect bilirubin, total bilirubin, or the ratio) are better to predict the prognosis in ASCVD.

Therefore, this study aims to evaluate whether the direct-indirect bilirubin ratio (DIBIL ratio) at admission could indicate the long-term prognosis of extremely high-risk ASCVD patients in north China.

Materials and methods

Study population

All enrolled patients were identified from the Cardiovascular Center of Beijing Friendship Hospital Database (CBD Bank). From Dec 2012 to Dec 2020, 12,763 ACS patients were evaluated as extremely high-risk. According to the 2018 AHA/ACC cholesterol guideline and Consensus of Chinese experts on lipid management in extremely high-risk ASCVD patients, the extremely high-risk ASCVD was identified as those who suffered more than 2 times severe ASCVD events, or those with 1-time severe ASCVD combined with more than 2 high-risk factors (Supplementary material 1). According to the flow chart (Fig. 1), 2503 were excluded according to the exclusion criteria, including (1) 556 patients lack data of serum bilirubin; (2) 85 patients were diagnosed with severe valvular diseases or cardiomyopathy; (3) 880 patients were meanwhile suffering infectious disease, rheumatic disease, hematological disease or neoplastic disease; (4) 134 patients were diagnosed with severe renal disease; (5) 155 patients with liver disease or increased liver enzymes; (6) 693 patients lost clinical or follow-up data. The final 10,260 included patients were divided into tertiles according to their DIBIL ratio levels (DIBIL ratio < 0.20 group, n = 3420; 0.20 ≤ DIBIL ratio < 0.26 group, n = 3420; DIBIL ratio ≥ 0.26, n = 3420). All patients were followed up till Oct 31, 2021, with a median follow-up of 41.7 months.
Data collection and definitions
This study was approved by the Institutional Review Board of Beijing Friendship Hospital Affiliated to Capital Medical University and all steps were carried out according to the Declaration of Helsinki. Patients’ basic characteristics, including their medical history, laboratory test values, imaging findings, and angiographic evaluation results were collected and verified by the medical recording system in Beijing Friendship Hospital. All the fasting blood samples were taken on the morning after PCI and the TB and DB and other laboratory parameters were measured by standard methods (the reference range for TB in our hospital is 3.42–17.1 umol/L, 0–6.84 umol/L for DB, and 0–12 umol/L for Indirect bilirubin). The incidence of MACCEs was reported during the hospitalization and follow-up period after the discharge, which was performed with a phone interview.

Clinical comorbidities are defined according to the following criteria: Hypertension: blood pressure ≥140/90 mmHg three times on at least two days, patients who are receiving antihypertensive drugs. DM: patients meet one of the following criteria: (1) receiving antidiabetic agents; (2) the typical symptoms of DM with FPG ≥7.0 mmol/L, and/or RBG ≥11.1 mmol/L, and/or 2-h plasma glucose level after OGTT ≥11.1 mmol/L. Dyslipidemia: fasting TC >200 mg/dL, and/or LDL-C >130 mg/dL, and/or TGs >150 mg/dL, and/or HDL-C <40 mg/dL, and/or receiving lipid-lowering drugs. AMI (including NSTEMI and STEMI): chest pain with new ST-segment changes and elevation of myocardial necrosis markers to at least twice the upper limit of the normal range. ACS: acute coronary syndrome (ACS) refers to a group of conditions that include ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina.

In this study, MACCEs were defined as all-cause death, CV death, non-fatal MI, stroke, cardiac rehospitalization, or revascularization [15]. CV death was defined as fatal stroke or MI, sudden death. All-cause death was defined as the incidence of death regardless of the reasons. Non-fatal stroke (both ischemic and hemorrhagic stroke) was defined as cerebral dysfunction due to a cerebral vascular occlusion or sudden rupture, which was diagnosed according to the signs of neurological dysfunction or imaging evidence. Cardiac rehospitalization refers to rehospitalization due to angina or heart failure. Any coronary revascularization was defined as revascularization of the target vessel or non-target vessels.

Statistical analysis
Continuous variables were shown as mean ± standard deviation (SD) or continuous variables with abnormal distribution were expressed as median (25th-75th percentile). Anova or Kruskal Wallis test was applied to compare the difference between groups. Categorical data were illustrated as numbers and percentages. The Pearson chi-square test or Fisher’s exact test was adopted to analyze the difference. Receiver-operating characteristic (ROC) curve analysis was adopted to identify the predictive effect of different markers and their optimal cut-off point value on MACCEs. Basic factors that correlated with all-cause death in the univariate analyzed model were enrolled in the multivariate model. Considering the competitive risk between all-cause death and other outcomes, we imported the competing risk model to identify the independent predictive effect of the DIBIL ratio on the sub-group of MACCEs. Competing risk regression curves were used to estimate the incidence of MACCEs and their subgroups. Integrated discrimination improvement (IDI) was also involved to determine the extent to which the addition of the DIBIL ratio improves the predictive power of the existing baseline risk model. All statistical tests were performed with IBM SPSS statistics 26, Stata/SE 15.1, and the R Programming Language. A two-tailed p-value < 0.05 was regarded as statistically significant.
| Variable | Total population | Low DIBIL ratio | Moderate DIBIL ratio | High DIBIL ratio | p value |
|----------|-----------------|-----------------|---------------------|------------------|---------|
|          | n = 10,260      | n = 3420        | n = 3420            | n = 3420         |         |
| Total bilirubin, umol/L | 13.75 ± 6.20 | 14.17 ± 6.39 | 13.69 ± 5.78 | 13.39 ± 6.40 | <0.001 |
| Direct bilirubin, umol/L | 2.64 ± 1.54 | 1.97 ± 0.94 | 2.54 ± 1.08 | 3.40 ± 2.01 | <0.001 |
| Indirect bilirubin, umol/L | 11.11 ± 10.6 | 12.20 ± 5.52 | 11.15 ± 4.72 | 9.99 ± 4.67 | <0.001 |
| Direct/indirect bilirubin ratio | 0.23 (0.18, 0.28) | 0.17 (0.15, 0.18) | 0.23 (0.21, 0.24) | 0.31 (0.28, 0.37) | <0.001 |
| Age, years | 63.9 ± 10.3 | 62.7 ± 10.3 | 64.1 ± 10.1 | 65.0 ± 10.4 | <0.001 |
| Male gender | 6911 (67.4) | 1974 (57.7) | 2328 (68.1) | 2609 (76.3) | <0.001 |
| BMI, kg/m² | 25.9 ± 3.5 | 25.8 ± 3.4 | 25.9 ± 3.5 | 25.9 ± 3.5 | 0.386 |
| SBP, mmHg | 130.9 ± 18.7 | 131.8 ± 18.7 | 131.1 ± 18.6 | 130.0 ± 18.8 | 0.001 |
| DBP, mmHg | 75.7 ± 11.6 | 76.3 ± 12.0 | 75.5 ± 11.5 | 75.3 ± 11.4 | 0.001 |
| Heart rate, bpm | 72 ± 12 | 71 ± 12 | 71 ± 12 | 72 ± 13 | 0.261 |

### Medical history

| Variable | Value |
|----------|-------|
| Current/ex-Smoker | 5930 (57.8) |
| Hypertension | 7154 (69.7) |
| Diabetes | 3665 (35.7) |
| Dyslipidemia | 4897 (47.7) |
| Previous Stroke | 1557 (15.2) |
| Previous MI | 1011 (9.9) |
| Past PCI | 1514 (14.8) |
| Past CABG | 200 (1.9) |

### Clinical presentation

| Variable | Value |
|----------|-------|
| STEMI | 1732 (16.9) |
| NSTEMI | 1599 (15.6) |
| UAP | 6929 (67.5) |

### Medication on admission

| Variable | Value |
|----------|-------|
| Antiplatelet agent | 3790 (36.9) |
| ACEI/ARB | 3502 (34.1) |
| Beta-blocker | 2261 (22.0) |
| Statins | 3266 (31.8) |

### Medication during hospitalization

| Variable | Value |
|----------|-------|
| Antiplatelet agent | 9936 (96.8) |
| ACEI/ARB | 5706 (55.5) |
| Beta-blocker | 7124 (69.4) |
| Statins | 9451 (92.1) |

### Laboratory data

| Variable | Value |
|----------|-------|
| WBC, 10⁹/L | 6.7 (5.5, 8.2) |
| Hemoglobin, g/L | 135.7 ± 18.6 |
| HcCRP, mg/L | 1.94 (0.75, 6.06) |
| RBG at admission, mmol/L | 7.4 (6.0, 9.8) |
| FPG, mmol/L | 5.5 (4.8, 6.7) |
| Albumin, g/L | 39.0 (36.8, 41.5) |
| ALT, U/L | 190 (13.0, 28.0) |
| AST, U/L | 198 (16.0, 19.0) |
| ALP, U/L | 75.0 (63.9, 89.0) |
| GGT, U/L | 240.0 (170.0, 360.0) |
| CHE | 8.2 (7.2, 9.2) |
| Creatinine, umol/L | 77.0 (66.7, 88.4) |
| eGFR, mL/min/1.73m² | 86.5 (72.9, 99.1) |
| TC, mmol/L | 4.18 (3.53, 4.89) |
| TGs, mmol/L | 1.39 (1.03, 1.98) |
| LDL-C, mmol/L | 2.36 (1.89, 2.89) |
Table 1 (continued)

| Variable | Total population | Low DIBIL ratio | Moderate DIBIL ratio | High DIBIL ratio | p value |
|----------|-----------------|----------------|---------------------|----------------|---------|
| HDL-C mmol/L | 1.04 (0.90, 1.23) | 1.09 (0.94, 1.29) | 1.03 (0.90, 1.21) | 1.00 (0.86, 1.17) | <0.001 |

Echocardiography

| Variable | n = 10,260 | n = 3420 | n = 3420 | n = 3420 |
|----------|------------|----------|----------|----------|
| LVEF (%) | 64.5 ± 8.0 | 64.5 ± 8.0 | 64.1 ± 8.5 | 62.8 ± 9.7 | <0.001 |

ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blockers, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, BMI: body mass index, CABG: Coronary Artery Bypass Grafting, CRP: c-reactive protein, Che: Cholinesterase, DBP: diastolic blood pressure, eGFR: estimated glomerular filtration rate, FPG: fast plasma glucose, GGT: gamma glutamyl transpeptidase, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, LVEF: left ventricular ejection fraction, MI: myocardial infarction, NSTEMI: non-ST elevated myocardial infarction, PCI: percutaneous coronary intervention, RBG: random blood glucose, SBP: systolic blood pressure, STEMI: ST-elevated myocardial infarction, TC: total cholesterol, TGs: triacylglycerol, UAP: unstable angina pectoris, WBC: white blood cells

Table 2 Angiography characteristics and treatment

| Variable | Total population | Low DIBIL ratio | Moderate DIBIL ratio | High DIBIL ratio | p value |
|----------|-----------------|----------------|---------------------|----------------|---------|
| LM/three-vessel | 6740 (65.7) | 2146 (62.7) | 2213 (64.7) | 2381 (69.6) | <0.001 |
| Proximal LAD | 2931 (28.6) | 1009 (29.5) | 969 (28.3) | 953 (27.9) | 0.304 |
| PCI/CABG | 6212 (60.5) | 2120 (62.0) | 2047 (59.9) | 2045 (59.8) | 0.107 |

CABG: Coronary Artery Bypass Grafting, LM: left main vessel, LAD: left anterior descending artery, PCI: percutaneous coronary intervention

Table 3 Clinical outcomes

| Variable | Total population | Low DIBIL ratio | Moderate DIBIL ratio | High DIBIL ratio | p value |
|----------|-----------------|----------------|---------------------|----------------|---------|
| All-cause death | 498 (4.9) | 87 (2.5) | 131 (3.8) | 280 (8.2) | <0.001 |
| CV death | 252 (2.5) | 46 (1.3) | 63 (1.8) | 143 (4.2) | <0.001 |
| Non-fatal MI | 376 (3.7) | 112 (3.3) | 112 (3.3) | 152 (4.4) | 0.010 |
| Cardiac rehospitalization | 2507 (24.4) | 724 (21.2) | 770 (22.5) | 1013 (29.6) | <0.001 |
| Revascularization | 710 (6.9) | 216 (6.3) | 204 (6.0) | 290 (8.5) | <0.001 |
| Stroke | 159 (1.5) | 32 (0.9) | 55 (1.6) | 72 (2.1) | <0.001 |
| Composite MACCEs | 2974 (29.0) | 810 (23.7) | 902 (26.4) | 1262 (36.9) | <0.001 |

CV: cardiovascular, MACCEs: Major Adverse Cardiac and Cerebrovascular events, MI: myocardial infarction

Fig. 3 Kaplan-Meier curves for composite MACCEs. (MACCEs: major adverse cardiac and cerebral events; HR, hazard ratio; CI, confidence interval)

Fig. 4 Kaplan-Meier curves for all-cause death(a), cardiac death (b), cardiac rehospitalization (c), stroke (d), non-fatal MI (e), revascularization (f) of the DIBIL ratio < 0.20 group (line 1), 0.20 ≤ DIBIL ratio < 0.26 group (line 2) and DIBIL ratio ≥ 0.26 group (line 3). (MI, myocardial infarction; DIBIL ratio, direct-indirect bilirubin ratio; HR, hazard ratio; CI, confidence interval)
### Table 4  Independent predictors of all-cause death

| | Univariate | | | | Multivariate | | |
|---|---|---|---|---|---|---|---|
| | HR (95%CI) | p value | | Adjusted HR (95%CI) | | Adjusted p value | |
| Total bilirubin, umol/L | 1.011 (0.997, 1.025) | 0.132 | | | | |
| Direct bilirubin, umol/L | 1.109 (1.079, 1.140) | <0.001 | 1.069 (1.035, 1.103) | | <0.001 |
| Indirect bilirubin, umol/L | 0.996 (0.976, 1.015) | 0.650 | | | | |
| Direct/indirect bilirubin ratio | 3.339 (2.352, 4.739) | <0.001 | 2.652 (1.577, 4.461) | | <0.001 |
| Age, years | 1.088 (1.078, 1.099) | <0.001 | 1.056 (1.042, 1.070) | | <0.001 |
| Male gender | 1.161 (0.967, 1.393) | 0.110 | | | | |
| BMI, kg/m² | 0.936 (0.911, 0.961) | <0.001 | 0.966 (0.938, 0.995) | | 0.023 |
| SBP, mmHg | 1.009 (1.004, 1.014) | <0.001 | 1.007 (1.001, 1.013) | | 0.027 |
| DBP, mmHg | 0.987 (0.979, 0.995) | 0.002 | 0.993 (0.982, 1.004) | | 0.225 |
| Heart rate, bpm | 1.024 (1.019, 1.030) | <0.001 | 1.014 (1.007, 1.020) | | <0.001 |
| **Medical history** | | | | | | |
| Current/ex-Smoker | 1.031 (0.864, 1.231) | 0.732 | | | | |
| Hypertension | 1.391 (1.132, 1.710) | 0.002 | 1.047 (0.817, 1.342) | | 0.716 |
| Diabetes | 1.412 (1.182, 1.686) | <0.001 | 0.878 (0.685, 1.215) | | 0.304 |
| Dyslipidemia | 0.854 (0.714, 1.021) | 0.084 | | | | |
| Previous Stroke | 2.170 (1.777, 2.649) | <0.001 | 1.427 (1.139, 1.788) | | 0.002 |
| Previous MI | 1.970 (1.575, 2.464) | <0.001 | 1.215 (0.899, 1.641) | | 0.206 |
| Past PCI | 1.380 (1.110, 1.716) | 0.004 | 1.199 (0.900, 1.596) | | 0.215 |
| Past CABG | 2.153 (1.404, 3.301) | <0.001 | 1.389 (0.842, 2.291) | | 0.199 |
| **Medication on admission** | | | | | | |
| Antiplatelet agent | 1.033 (0.863, 1.237) | 0.722 | | | | |
| ACEI/ARB | 1.060 (0.882, 1.274) | 0.536 | | | | |
| Beta-blocker | 0.783 (0.625, 0.980) | 0.033 | 0.865 (0.663, 1.128) | | 0.284 |
| Statins | 0.699 (0.568, 0.862) | 0.001 | 0.789 (0.615, 1.013) | | 0.063 |
| **Laboratory data** | | | | | | |
| WBC, 10⁹/L | 1.047 (1.011, 1.084) | 0.010 | 1.038 (0.995, 1.083) | | 0.085 |
| Hemoglobin, g/L | 0.988 (0.985, 0.991) | <0.001 | 0.995 (0.990, 1.000) | | 0.032 |
| HsCRP, mg/L | 1.033 (1.026, 1.041) | <0.001 | | | | |
| RBG at admission, mmol/L | 1.062 (1.041, 1.084) | <0.001 | | | | |
| FPG, mmol/L | 1.104 (1.071, 1.139) | <0.001 | | | | |
| HbA1c, % | 1.176 (1.111, 1.243) | <0.001 | 1.169 (1.085, 1.260) | | <0.001 |
| Albumin, g/L | 0.858 (0.839, 0.877) | <0.001 | 0.970 (0.943, 0.998) | | 0.034 |
| ALT, U/L | 0.988 (0.982, 0.995) | 0.001 | 0.990 (0.983, 0.998) | | 0.009 |
| AST, U/L | 1.001 (1.001, 1.002) | 0.086 | | | | |
| ALP, U/L | 1.008 (1.004, 1.011) | <0.001 | | | | |
| GGT, U/L | 1.002 (1.000, 1.004) | 0.54 | | | | |
| ChE, | 0.685 (0.647, 0.725) | <0.001 | | | | |
| Creatinine, umol/L | 1.025 (1.021, 1.029) | <0.001 | | | | |
| eGFR, ml/min/1.73m² | 0.961 (0.957, 0.966) | <0.001 | 0.988 (0.981, 0.994) | | <0.001 |
| TC, mmol/L | 0.910 (0.833, 0.994) | 0.037 | 0.976 (0.870, 1.094) | | 0.674 |
| TGs, mmol/L | 0.720 (0.639, 0.811) | <0.001 | 0.924 (0.813, 1.050) | | 0.224 |
| LDLC, mmol/L | 0.943 (0.837, 1.063) | 0.337 | | | | |
| HDLC, mmol/L | 0.783 (0.558, 1.098) | 0.156 | | | | |
| **Echocardiography** | | | | | | |
| LVEF | 0.005 (0.003, 0.011) | <0.001 | 0.034 (0.013, 0.091) | | <0.001 |
| **Angiography findings** | | | | | | |
| LM/three-vessel | 2.936 (2.284, 3.774) | <0.001 | 1.666 (1.248, 2.224) | | 0.001 |
| Proximal LAD | 1.411 (1.172, 1.700) | <0.001 | 1.026 (0.832, 1.265) | | 0.813 |
| PCI/CABG | 1.049 (0.876, 1.258) | 0.601 | | | | |
| **Medication during hospitalization** | | | | | | |
### Results

**Baseline characteristics of patients**

We finally enrolled 10,260 diagnosed with ACS according to our exclusive and inclusive criteria (Fig. 1). We firstly compared the DIBIL ratio, DBIL, TBIL, and IBIL, and identified that the DIBIL ratio is the best biomarker to predict the all-cause death in our enrolled patients (Fig. 2), the area under ROC curves (AUCs) of the DIBIL ratio for predicting the occurrence of all-cause death was 0.668, the sensitivity was 51.61% and the specificity was 74.29%. Contrasted with DBIL, IBIL and TBIL, DIBIL ratio shows a larger AUC (p < 0.001) (Supplementary material 2).

All enrolled patients were divided into tertiles according to their DIBIL ratio levels (DIBIL ratio ≤ 0.20 group, n = 3420; 0.20 < DIBIL ratio < 0.26 group, n = 3420; DIBIL ratio ≥ 0.26, n = 3420). Tables 1 and 2 illustrated the baseline and procedural characteristics of all 10,260 patients with complete follow-up information, with available outcomes information.

**DIBIL ratio predicted the occurrence of a poor prognosis**

During the follow-up period, the incidence of composite MACCEs is 2974 (29.0%) in the total enrolled population, in the low DIBIL ratio group the incidence is 810 (23.7%), and 902 (26.4%) in the moderate DIBIL ratio group, 1262 (36.9%) in high DIBIL ratio group (Table 3). The Kaplan-Meier curves show that the cumulative rate of composite MACCE (Fig. 3) was not statistically different between the three groups. But the high DIBIL ratio group had a significantly higher cumulative rate of all-cause death (Fig. 4a) and CV death (Fig. 4b). In addition, the cumulative rate is also shown no statistical difference in cardiac rehospitalization (Fig. 4c), stroke (Fig. 4d), non-fatal MI (Fig. 4e), and revascularization (Fig. 4f).

In Table 4, the univariate and multivariate Cox regression analyses were employed to predict the incidence of all-cause death. According to the univariate analysis, the predictor linked to all-cause death occurrence were direct bilirubin, DIBIL ratio, age, BMI, systolic blood pressure, heart rate, hypertension history, diabetes history, previous stroke, previous MI, past PCI and CABG, β-blocker, and statin use, WBC, hemoglobin, hs-CRP, RBG at admission, FPG, HbA1c, albumin, ALT, ALP, ChE, creatinine, eGFR, TC, TGs, LVF, LM or three-vessel involved, antiplatelet agents and statin use during hospitalization. FPG, RBG at admission, TGs, and HbA1c had a high correlation (p < 0.001). ALT, ALP and ChE also had a great correlation (p < 0.001). Creatinine was significantly correlated with eGFR (p < 0.001), meanwhile, hs-CRP was significantly correlated with WBC (p < 0.001). Therefore, FPG, RBG at admission, ALP, ChE, creatinine, and hs-CRP were not included in the final multivariate model. In the following multivariate Cox proportional hazards, regression analysis indicated that DIBIL ratio, age, BMI, systolic blood pressure, heart rate, previous stroke, hemoglobin, HbA1c, albumin, ALT, eGFR, LVF, LM, or three-vessel involved independently predicted the incidence of all-cause death in patients with extremely high-risk of ASCVDs.

Table 5 presented the competing risk regression analysis for MACCEs. On unadjusted competing risk modeling, the cumulative incidence of all-cause death, CV death, and nonfatal stroke increased significantly with elevated DIBIL ratio levels (p < 0.05). Multivariate-adjusted hazard ratio (HR) also indicated that a high DIBIL ratio was correlated with a high incidence of all-cause death, CV death (p < 0.05).

**Enhancing the impact of DIBIL ratio on predictive value for all-cause death**

Table 6; Fig. 5 showed that compared with total bilirubin, DB, IDB, DIBIL ratio significantly improved the reclassification and discrimination ability beyond the baseline risk model with IDI 0.004(0.010), p < 0.001; C-index 0.805(0.783–0.827), p < 0.001.

**Discussion**

To our knowledge, this is the first study to explore the relationship between the DIBIL ratio and MACCEs in extremely high-risk ASCVD patients. The main findings of our study include: (1) The AUC of the DIBIL ratio is
Conclusively, we confirmed that the DIBIL ratio was positively interrelated to increased poor prognosis. ASCVD remained the leading cause of mortality in China, it’s extremely necessary to assign risk estimates to apply prevention strategies. Patients with extremely high-risk ASCVD usually suffered higher morbidity and mortality potential (30% or greater 10-year MACCEs risk) [16]. Therefore, more and more studies focused on figuring out potential biomarkers for better management of this population.

As the product of heme catabolism, bilirubin has been investigated as a biomarker for the prognosis of ASCVD. However, there are many controversies about this parameter. On the one hand, Yue et al. [17] reported that increased direct bilirubin was associated with more all-cause death in ACS patients. Chenbo and colleagues [12] also found that high TB and DB but not IDB was associated with a higher risk of MACCEs in Chinese ACS. This trend is consistent with our findings. While exploring the underlying mechanisms, Gupta et al. [9] reported that bilirubin could act as a scavenger of the reactive oxygen species independent of the conjugated or unconjugated forms. Additionally, bilirubin was reported to reduce arterial stiffness according to a preclinical test in diabetic mice [18]. Also, preclinical studies on mice demonstrated the protective effects of bilirubin on hypertension induced by angiotensin-II [19]. On the other hand, some studies found an inverse association between plasma bilirubin and total mortality. HAPIEE cohort [20] indicated that there was a negative correlation between bilirubin and mortality. In addition, other studies reported a U-shaped association between TBIL, IDB, and CHD risk. From the biological aspects, first, a high level of bilirubin is an indicator of oxidative stress and inflammation, which is a friend and foe to the pathological process of ASCVD. Second, a high level of bilirubin is an indicator of liver dysfunction, which may also cause cell apoptosis. From the clinical aspects, we found that this divergence may be due to several aspects, first, the study design and the definitions of the endpoints have a great impact on the results. Second, some studies elucidated the relationship between bilirubin and coronary artery diseases in random patients but not under acute stress conditions, such as ACS, which may cause antipodal conclusions. Currently, several studies performed to evaluate the relationship between bilirubin and acute coronary syndrome and found that the major adverse cardiac events were more frequent in the high bilirubin group [21]. This conclusion is consistent with our study. Third, when patients suffered ACS especially those comorbid with heart failure, there is usually evidence of liver dysfunction, such as the increased aspartate amino transferase and alanine aminotransferase [17], increased bilirubin could also reflect liver dysfunction, from this perspective, higher

Table 5  Competing risk model of clinical outcomes  

| All-cause death | Unadjusted HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
|-----------------|------------------------|--------|----------------------|--------|
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 1.343 (1.024, 1.761) | 0.033 | 1.269 (0.954, 1.688) | 0.102 |
| DIBIL ratio ≥ 0.26 | 2.220 (1.742, 2.829) | <0.001 | 1.829 (1.405, 2.381) | <0.001 |
| CV death | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 1.202 (0.821, 1.670) | 0.345 | 1.152 (0.772, 1.717) | 0.489 |
| DIBIL ratio ≥ 0.26 | 1.966 (1.392, 2.776) | <0.001 | 1.600 (1.103, 2.321) | 0.013 |
| Non-fatal MI | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 0.904 (0.696, 1.175) | 0.452 | 0.922 (0.700, 1.215) | 0.565 |
| DIBIL ratio ≥ 0.26 | 0.955 (0.745, 1.225) | 0.718 | 0.918 (0.689, 1.222) | 0.556 |
| Cardiac rehospitalization | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 0.958 (0.865, 1.060) | 0.406 | 0.942 (0.847, 1.048) | 0.272 |
| DIBIL ratio ≥ 0.26 | 1.040 (0.945, 1.146) | 0.423 | 0.997 (0.896, 1.110) | 0.959 |
| Revascularization | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 0.831 (0.684, 1.011) | 0.064 | 0.839 (0.683, 1.029) | 0.092 |
| DIBIL ratio ≥ 0.26 | 0.985 (0.823, 1.178) | 0.868 | 0.965 (0.791, 1.178) | 0.725 |
| Stroke | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 1.592 (1.025, 2.474) | 0.039 | 1.378 (0.873, 2.175) | 0.169 |
| DIBIL ratio ≥ 0.26 | 1.586 (1.043, 2.412) | 0.031 | 1.189 (0.756, 1.870) | 0.453 |
| Composite MACCEs | | | |
| DIBIL ratio<0.20 | Ref | Ref | | |
| 0.20 ≤ DIBIL ratio<0.26 | 0.959 (0.866, 1.062) | 0.419 | 0.945 (0.850, 1.052) | 0.303 |
| DIBIL ratio ≥ 0.26 | 0.991 (0.899, 1.092) | 0.858 | 0.959 (0.862, 1.068) | 0.451 |

CV: cardiovascular, DIBIL: direct/indirect bilirubin ratio, MACCEs: Major Adverse Cardiac and Cerebrovascular events, MI: myocardial infarction

significantly higher than DBIL, TBIL, and IBIL. indicating that DIBIL ratio is a better biomarker for the prediction of all-cause death; (2) the incidences of MACCEs significantly increased with a higher DIBIL ratio; (3) The DIBIL ratio is an independent predictor of all-cause death; (4) The addition of DIBIL ratio to a baseline risk model had an enhance impact on the predictive value for death.
serum bilirubin could contribute to increased cardiac risk. Indirect bilirubin is metabolized and transferred into direct bilirubin in the liver, depending on liver function to a great extent. All the above papers analyzed the relationship between total, indirect or direct bilirubin and the endpoints, which may draw different even opposite conclusions. Considering this issue, to resolve the discrepancies, we first investigated the prognostic value of DIBIL ratio, total bilirubin, direct bilirubin, and indirect bilirubin in our enrolled patients, and found that the DIBIL ratio is the best indicator.

In this study, we evaluated the prognostic value of the DIBIL ratio in patients with extremely high-risk of ASCVD in different types of MACCEs and its subgroups and found that a higher DIBIL ratio was related to a higher incidence of all-cause death and CV death in competing risk model. Additionally, we also found that adding the DIBIL ratio to the baseline risk model had an enhancing impact on the predictive value for all-cause death. We held the idea that all the above findings may help physicians to predict the occurrence of clinical events and make relative strategies to prevent them. Another novelty of our study is that we identified that the DIBIL ratio was closely associated with all-cause death in different subgroups divided by age, BMI, systolic blood pressure, heart rate, previous stroke, hemoglobin, HbA1c, albumin, ALT, eGFR, LVEF, LM/three-vessel involved. Similar to previous studies, multiple linear regression indicated that factors including age, heart rate, diabetes, LM, or three-vessel involved related to total bilirubin [14]. ALT is a biomarker of liver function, increased ALT usually indicated liver dysfunction, in our study, we found that the DIBIL ratio is related to ALT and albumin after multiple regression analysis, this finding revealed that in ACS patients, especially those with extremely high-risk ASCVD, many patients also suffer liver dysfunction, which inferred that we should pay attention to the liver protection while we used bilirubin to predict patients’ prognosis. Published evidence has reported a negative association between bilirubin concentrations and metabolic syndrome and diabetes [22]. However, in our study, we found that a higher DIBIL ratio is positively related to HbA1c, this may be due to the patients included in the study, in our study, we enrolled patients with extremely high-risk ASCVD, while Lin’s work mainly focused on children and adolescents. More studies should be done to retest our conclusions in the future. Accordingly, compared with simple direct or indirect bilirubin, the DIBIL ratio may be a better marker for prognosis. Finally, although our data showed that the DIBIL ratio increased the discrimination ability beyond the baseline risk model with IDI 0.004(0, 0.010), p<0.001,

### Table 6  Predictive value and predictive power of various models

| IDI | C-index |
|-----|---------|
|     | Index 95% CI p value | Index 95% CI p value |
| Baseline risk model | 0.801 0.778, 0.823 <0.001 |
| Total bilirubin | 0.002 0.004 0.040 0.082 0.808, 0.848 <0.001 |
| Direct bilirubin | 0.002 0.004 <0.001 0.803 0.782, 0.814 <0.001 |
| Indirect bilirubin | 0.001 0.002 0.182 0.801 0.776, 0.805 <0.001 |
| Direct/Indirect bilirubin ratio | 0.004 0.010 <0.001 0.805 0.783, 0.827 <0.001 |

Baseline risk model including age, BMI, SBP, heart rate, history of stroke, hemoglobin, albumin, HbA1c ALT, eGFR, LVEF, LM/three vessels in angiography findings.

ALT: alanine aminotransferase, BMI: body mass index, eGFR: estimated glomerular filtration rate, HbA1c: glycated hemoglobin, IDI, integrated discrimination improvement, SBP: systolic blood pressure, LVEF: left ventricular ejection fraction, LM: left main vessel.
this improvement is not significant, one possible explanation of this may be due to the excellent ability of the baseline risk model.

There are several limitations of our study. First, this was a single-center study only collecting a sample from Beijing Friendship Hospital, thus, there is no evidence to generalize conclusions in our study to other organizations. Second, this is a retrospective observed study, in the future, more prospective studies even RCTs are required to confirm our findings. Third, some laboratory parameters in our study were only measured once during hospitalization, which could cause potential bias. In addition, the biological mechanisms linking bilirubin and ASCVD risk are still unclear, future studies in this field may be necessary.

Conclusion

Conclusively, this study firstly demonstrated that an increased DIBIL ratio was an independent predictor of poor prognosis in patients diagnosed with ACS. Additionally, the DIBIL ratio along with the baseline risk model exerts an enhancing impact on the predictive value for all-cause death.

Abbreviations

ACS acute coronary syndrome  
ALP Alkaline Phosphatase  
ALT alanine aminotransferase  
AMI acute myocardial infarction  
ASCVD atherosclerotic cardiovascular diseases  
BMI body mass index  
CAD Coronary artery disease  
CABG Coronary Artery Bypass Grafting  
CBD Center of Beijing Friendship Hospital Database  
CRP C-reactive protein  
CV death cardiac and cerebral death  
DB direct bilirubin  
DIBIL ratio direct-indirect bilirubin ratio  
DBIL direct bilirubin  
TBIL total bilirubin  
IBIL indirect bilirubin  
DM diabetes mellitus; eGFR estimated glomerular filtration rate; FPG fast plasma glucose; HbA1c glycated hemoglobin; HDL-C high-density lipoprotein cholesterol; IDB indirect bilirubin  
IDI integrated discrimination improvement  
IQR interquartile range  
LDL-C low-density lipoprotein cholesterol  
LM left main vessel  
LVEF left ventricular ejection fraction  
MACCEs major adverse cardiac and cerebral events  
NSTEMI non-ST segment elevation myocardial infarction  
OGTT oral glucose tolerance test  
PCI percutaneous coronary intervention  
RBG random blood glucose  
ROC Receiver-operating characteristic  
SBP systolic blood pressure  
SCORE systematic coronary risk evaluation  
PCE Pooled Cohort Equations  
SD standard deviation  
STEMI ST segment elevation myocardial infarction  
TC total cholesterol  
TG triglyceride  
WBC white blood cells

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02894-1.

Supplementary Material 1: Extreme high-risk ASCVD

Supplementary Material 2: Z test of AUCs in Figure 2

Acknowledgements

We gratefully acknowledge the contributions of all staff who work on the CBD Bank.

Author contributions

Jiayu Li and Yanguo Xin drafted the manuscript, Jiayu Li and Jingye Li carried out the statistical analysis, Meng Meng participated in study data collection, Li Zhou and Hui Qiu contributed discussion and edited the manuscript. Hui Chen revised the manuscript. Hongwei Li designed and supervised the project.

Funding

This work was supported by the National Key R&D Program of China (Grant No.2021ZD0111004), the National Natural Science Foundation of China (Grant No.82078357) and Beijing Key Clinical Subject Program.

Data availability

The datasets generated and/or analyzed during the current study are not publicly available due to the provisions of the CBD Bank but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study data collections were approved by the Institutional Review Board of Beijing Friendship Hospital affiliated with Capital Medical University, and informed consent was obtained from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 5 March 2022 / Accepted: 11 October 2022

Published online: 10 November 2022

References

1. Li H, Ge J. Cardiovascular diseases in China: Current status and future perspectives. Int J Cardiol Heart Vasc. 2015;6:25–31. doi:https://doi.org/10.1016/j.ijcha.2014.10.002.
2. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: A systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–72. doi:https://doi.org/10.1016/s0140-6736(15)00551-6.
3. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34. doi:https://doi.org/10.1056/NEJMoa050647.
4. Comoy RM, Pryorla K, Fitzgerald AF, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(1):987–1003. doi:https://doi.org/10.1016/s0195-668x(03)00114-3.
5. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. doi:https://doi.org/10.1161/CIR.0000000000000437.
6. Guzel MDemirMO,AAktan,T, Aslan B, H.Simsek. Prognostic Significance of Monocyte to High-density Lipoprotein Ratio in Patients With Chronic Coronary Artery Occlusion. Dicle Tip Dergisi. 2022;49(1):2–20.
7. Wu TT, Zheng YY, Chen Y, et al. Monocyte to high-density lipoprotein cholesterol ratio as long-term prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention. Lipids Health Dis. 2019;18(1):180. doi:https://doi.org/10.1186/s12944-019-1116-2.

8. Zhang DF, Batioula G, Wu TT, et al. An elevated monocyte-to-high-density lipoprotein-cholesterol ratio is associated with mortality in patients with coronary artery disease who have undergone PCI. Biosci Rep 2020;40(8) doi:https://doi.org/10.1042/bsr2020108.

9. Gupta N, Singh T, Chaudhary R, et al. Bilirubin in coronary artery disease: Cytotoxic or protective? World J Gastrointest Pharmacol Ther. 2016;7(4):469–76. doi:https://doi.org/10.4292/wjgpt.v7.i4.469.

10. Pineda S, Bang OY, Saver JL, et al. Association of serum bilirubin with ischemic stroke outcomes. J Stroke Cerebrovasc Dis. 2008;17(3):147–52. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2008.01.009.

11. Chen Z, He J, Chen C, et al. Association of Total Bilirubin With All-Cause and Cardiovascular Mortality in the General Population. Front Cardiovasc Med. 2021;8:670768. doi:https://doi.org/10.3389/fcvm.2021.670768.

12. Xu C, Dong M, Deng Y, et al. Relation of Direct, Indirect, and Total bilirubin to Adverse Long-term Outcomes Among Patients With Acute Coronary Syndrome. Am J Cardiol. 2019;123(8):1244–48. doi:https://doi.org/10.1016/j.amjcard.2019.01.019.

13. Tang C, Qian H, Wang D, et al. Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. Biomed Res Int. 2019;2019:5243589. doi:https://doi.org/10.1155/2019/5243589.

14. Gao F, Qiang H, Fan XJ, et al. Higher serum total bilirubin predicts high risk of 3-year adverse outcomes in patients undergoing primary percutaneous coronary intervention. Ther Clin Risk Manag. 2019;15:811–21. doi:https://doi.org/10.2147/rcrm.S203433.

15. Xin YG, Zhang HS, Li YZ, et al. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Int J Cardiol. 2017;228:275–79. doi:https://doi.org/10.1016/j.ijcard.2016.11.160.

16. Ye P. [Highlight the importance of reaching the target goal of LDL-C in extremely-high-risk ASCVD patients: follow the trend of combined use of lipid lowering medications], Zhonghua xin xue guan bing za zhi. 2020;48(2):998–99. doi:https://doi.org/10.3760/cma.j.cn112148-20200730-00066.

17. Liu Y, Zhang C, Jiang L, et al. Direct Bilirubin Levels Predict Long-Term Outcomes in Patients With Acute Coronary Syndrome Under Different Glucose Metabolism Status: A 6.5-Year Cohort Study of Three-Vessel Disease. Front Cardiovasc Med. 2021;8:715539. doi:https://doi.org/10.3389/fcvm.2021.715539.

18. Jian Liu, Li Wang, Xiao Yu, et al. Tian Unconjugated Bilirubin Mediates Heme Oxygenase-1–Induced Vascular Benefits in Diabetic Mice. American Diabetes Association.2015;64(5):1564–75. doi:https://doi.org/10.2337/db14-1391.

19. LeBlanc RM, Navar LG, Botros FT, Gööz M. Bilirubin exerts renoprotective effects in angiotensin II hypertension. 2010;340(2):144–6.

20. Vitek L, Hubacek JA, Pajak A, et al. Association between plasma bilirubin and mortality. Ann Hepatol 2019;18(2):379–85. doi:https://doi.org/10.1016/j.ahep.2019.02.001.

21. Gul M, Uyar1 H, Ergelen M, Akıgül O, Karaca G, Turek S, Uğur M, Ertürk M, Kul S, Surjat O, Bozbay M, Uslu N. Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2013;111(2):166–71.

22. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, Lin JL. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009;203(2):563–568.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.